Posard Matthew L. — SEC insider filings
SEC reporting owner CIK 1543792. 25 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2021-01-13 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 3 filings — 146,398 shares, $2,225,496 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 18 legs across 6 filings — 109,107 shares, $7,498,532 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: purchase of 62,500 shares @ $16.00 ($1,000,000) in Talis Biomedical Corp, filed 2021-02-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. (HALO) | Director | 12 | — | 18 legs · 109,107 sh · $7,498,532 | 10 |
| Talis Biomedical Corp (TLIS) | Director | 3 | 1 leg · 62,500 sh · $1,000,000 | — | 2 |
| DermTech, Inc. (DMTK) | Director | 4 | 1 leg · 33,898 sh · $999,991 | — | 4 |
| Nautilus Biotechnology, Inc. (NAUT) | Director | 6 | 4 legs · 50,000 sh · $225,505 | — | 5 |
Insider filings — Posard Matthew L.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 3,400 @ $96.17 · Sale (S): 1,600 @ $96.97 | EDGAR |
| 2026-10-02 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 730 @ $107.17 · Sale (S): 3,300 @ $108.45 · Sale (S): 1,100 @ $109.57 · Sale (S): 100 @ $110.04 | EDGAR |
| 2026-09-17 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 3,100 @ $106.13 · Sale (S): 3,000 @ $106.83 · Sale (S): 8,896 @ $108.04 · Sale (S): 4,000 @ $108.99 | EDGAR |
| 2026-06-22 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 3,796 @ $0 · Grant/award (A): 6,040 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 4,165 @ $0 · Grant/award (A): 5,750 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 10,000 @ $55.72 · Sale (S): 10,000 @ $56.19 · Sale (S): 9,881 @ $57.70 | EDGAR |
| 2024-06-17 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 10,000 @ $50.01 · Sale (S): 10,000 @ $50.62 | EDGAR |
| 2024-04-29 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 6,501 @ $0 · Grant/award (A): 8,804 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Talis Biomedical Corp (TLIS) | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | DermTech, Inc. (DMTK) | Grant/award (A): 35,714 @ $0 | EDGAR |
| 2023-05-09 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 8,065 @ $0 · Grant/award (A): 11,371 (derivative) @ $0 | EDGAR |
| 2022-12-06 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Sale (S): 10,000 @ $58.80 · Sale (S): 10,000 @ $55.74 · Sale (S): 10,000 @ $56.12 | EDGAR |
| 2022-06-16 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 86,467 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Talis Biomedical Corp (TLIS) | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | DermTech, Inc. (DMTK) | Grant/award (A): 26,480 @ $0 | EDGAR |
| 2022-05-06 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 6,206 @ $0 | EDGAR |
| 2021-12-01 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Purchase (P): 20,000 @ $4.57 · Purchase (P): 10,000 @ $4.50 · Purchase (P): 10,000 @ $4.46 · Purchase (P): 10,000 @ $4.45 | EDGAR |
| 2021-05-28 | 4 | DermTech, Inc. (DMTK) | Grant/award (A): 4,497 @ $0 · Grant/award (A): 4,661 @ $0 | EDGAR |
| 2021-05-06 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 5,230 @ $0 | EDGAR |
| 2021-02-19 | 4 | Talis Biomedical Corp (TLIS) | Purchase (P): 62,500 @ $16 | EDGAR |
| 2021-01-13 | 4 | DermTech, Inc. (DMTK) | Purchase (P): 33,898 @ $29.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1543792 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs